0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > LYPD3

LYPD3

Brief Information

Name:Ly6/PLAUR domain-containing protein 3
Target Synonym:GPI-Anchored Metastasis-Associated Protein C4.4A Homolog,MIG-C4,C4.4A,GPI-Anchored Metastasis-Associated Protein Homolog,2310061G07Rik,UNQ491/PRO1007,Ly6/PLAUR domain-containing protein 3,LYPD3,LY6/PLAUR Domain Containing 3,Matrigel-Induced Gene C4 Protei
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 1 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
LY3-H52H5 Human Human LYPD3 / C4.4A Protein, His Tag
LY3-H52H5-structure
LY3-H52H5-sds

Synonym Name

LYPD3,MIG-C4,C4.4A

Background

Ly6/PLAUR domain-containing protein 3 (LYPD3) is also known as MIG-C4 ,C4.4A, GPI-anchored metastasis-associated protein C4.4A homolog and Matrigel-induced gene C4 protein,which is a cell membrane protein containing two UPAR/Ly6 domains. LYPD3 is expressed in placenta, skin and urothelium. LYPD3 is found in the majority of primary and metastatic transitional cell carcinomas (TCCs) and as well in breast cancer tissues, but not in adjacent normal tissues. LYPD3 play a role in supporting cell migration and it is not only probably involved in urothelial cell-matrix interactions, but also in tumor progression.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Lupartumab amadotin BAY-1129980 Phase 1 Clinical Bayer Ag Neoplasms Details

This web search service is supported by Google Inc.

totop